BACKGROUND: Danon disease is an X-linked disorder that leads to fatal cardiomyopathy caused by a deficiency in lysosome-associated membrane protein-2 (LAMP2). In female patients, a later onset and less severe clinical phenotype have been attributed to the random inactivation of the X chromosome carrying the mutant diseased allele. We generated a patientspecific induced pluripotent stem cell (iPSCs)-based model of Danon disease to evaluate the therapeutic potential of Xi-chromosome reactivation using a DNA methylation inhibitor.
A utophagy is an essential cellular mechanism to degrade cytoplasmic organelles within the lysosome to recycle cytoplasmic materials and to eliminate dysfunctional proteins/organelles in response to starvation and stress. 1 Lysosomal protein degradation constitutes the final step during the process of autophagy in which lysosome-associated membrane protein-2 (LAMP2) plays a critical role in mediating fusion of autophagosomes with lysosomes to form autolysosomes. [2] [3] [4] The LAMP2 gene is located at Xq24, and its loss-of-function mutation causes Danon disease. 5, 6 Danon disease is characterized by cellular autophagy failure with accumulation of glycogen granules and intracytoplasmic vacuoles that contain autophagic materials. This causes skeletal myopathy, various degrees of mental retardation, and progressive fatal cardiomyopathy. [7] [8] [9] Danon disease causes early-onset fatal cardiomyopathy in affected male patients, who often die of ventricular tachyarrhythmias or progressive heart failure before 25 years of age in the absence of a heart transplantation. [9] [10] [11] On the contrary, affected female patients usually present with disease onset ≈15 years later and are able to survive to middle age. [9] [10] [11] [12] Although the exact mechanism of this sex difference remains unclear, it has been attributed to skewed inactivation of the LAMP2 gene on the X chromosome in affected female subjects. 9, [13] [14] [15] We describe a mother and 2 sons who suffered from Danon disease caused by a nonsense mutation (c.520C>T) at exon 4 of the LAMP2 gene diagnosed by whole-exome sequencing. First, we generated induced pluripotent stem cells (iPSCs) from the somatic cells of these affected subjects and differentiated them into cardiomyocytes in vitro to model the pathophysiology of Danon disease. Next, we used the patient-specific iPSC cardiomyocyte (iPSC-CMs) platform for drug screening and discovered that the DNA methylation inhibitor 5-aza-2'-deoxycytidine (5AdC) could partially reactivate the silenced wide-type allele of the LAMP2 gene to ameliorate the pathological phenotypes caused by autophagy dysfunction in Danon disease.
METHODS Patients
The proband (female Pt-I-1) was a 41-year-old woman who presented with progressive worsening of dyspnea and ankle edema ( Figure 1A ). ECG revealed atrial fibrillation with poor R-wave progression. Transthoracic echocardiogram showed dilated left ventricles (LVs) with an impaired LV ejection fraction of 30% and moderate mitral regurgitation. Coronary angiogram showed normal coronary arteries. Cardiac magnetic resonance imaging demonstrated patchy gadolinium enhancement over the anterior wall and impaired LV ejection fraction of 30%. She was treated having idiopathic dilated cardiomyopathy and underwent heart transplantation 7 years later because of progressive biventricular failure. Three years after her initial presentation, her younger son (male Pt-II-2) was diagnosed with a fatty liver, myotonic dystrophy, and hypertrophic cardiomyopathy at 14 years of age. Further screening of her family revealed that her elder son who was 20 years old (male Pt-II-1) also suffered from hypertrophic cardiomyopathy. Their ECG showed a short PR interval with delta wave and LV hypertrophy. Cardiac magnetic resonance imaging revealed LV hypertrophy with impaired LV function (Video I in the online-only Data Supplement).
In view of the diverse clinical phenotypes of the mother and her sons, we performed whole-exome sequencing in the proband as reported previously. 16 We established that she carried a nonsense mutation (c.520C>T) at exon 4 of the LAMP2 gene ( Figure 1B and 1C ). This LAMP2 mutation has been described previously in Danon disease. 17 Subsequently, both of her sons were confirmed to carry the same mutation, but the mutation was not evident in any of her 4 siblings ( Figure 1A and 1B). Electronic microscopy of myocardial samples of the explanted heart of Pt-I-1 demonstrated myocardial disarray with diffuse accumulation of glycogen granules in the cardiomyocytes ( Figure 1D ). Further immunological and histological examination revealed a mosaic pattern of LAMP2-positive (≈47%) and LAMP2-negative (≈53%) cardiomyocytes. This mosaic pattern of LAMP2 protein distribution was similar to another patient with Danon disease whom we have described previously. 18 In addition, accumulation of microtubule-associated protein 1A/1B light chain 3 (LC3) punctae, an autophagosome marker, was observed in ≈26% of cardiomyocytes ( Figure 2A ). Furthermore, ≈38% of the cardiomyocytes showed heavy glycogen deposition ( Figure 2B ). These histological findings further confirmed the diagnosis of Danon disease.
The study was approved by the local Institutional Review Board of the Queen Mary Hospital, Hong Kong, and was registered at the Clinical Trial Center, University of Hong Kong (No. HKCTR-725; http://www.hkclinicaltrials.com). The study was performed from October 2009 to March 2014, and all patients provided written informed consent.
Clinical Perspective
What Is New?
• We successfully generated induced pluripotent stem cell-derived cardiomyocytes from Danon patients with LAMP2-c.520C>T mutation and recapitulated the disease phenotypes such as excessive glycogen granule and autophagosome accumulation with impaired contractile function. • The preselection of the somatic cells with distinct X-chromosome inactivation status offers a unique way to generate isogenic induced pluripotent stem cells that carry either the wild-type or the mutant LAMP2 allele.
What Are the Clinical Implications?
• These isogenic induced pluripotent stem cells represent a powerful tool to show the distinctive disease phenotypes of X-linked related diseases and reveal the novel application of DNA demethylating agent 5-aza-2'-deoxycytidine to unsilence the inactivated wild-type allele and to ameliorate the disease phenotype.
Identification of the LAMP2-c.520C>T mutation
Genomic DNA samples were extracted from EDTA blood and subjected to whole-exome sequencing analysis (Methods in the online-only Data Supplement).
Histological and Immunohistochemistry Studies
Myocardial samples of the explanted heart of Pt-I-1 and the iPSCs-CMs were examined by electron microscopy and periodic acid-Schiff staining, respectively, to detect glycogen accumulation (Methods in the online-only Data Supplement). The tissue distribution of LAMP2 and other proteins of interest was evaluated by immunofluorescence microscopy with specific antibodies ( Table I in 
Generation of iPSCs
Skin samples were collected from Pt I-1 and Pt II-1 during the device implant procedure to yield dermal fibroblasts, 16 and urinary epithelial cells (Pt-II-2) were collected and expanded to generate iPSCs (Methods in the online-only Data Supplement). Although the primary fibroblasts derived from Pt-I-1 revealed a mosaic pattern of LAMP2 protein production ( Figure 3A ), the fibroblasts that expressed wild-type LAMP2-WT allele showed preference in reprogramming, so it was not possible to obtain any iPSC colonies that expressed the mutant allele (LAMP2c.520C>T). We therefore further subcloned her fibroblasts to prepare a population that expressed only the LAMP2c.520C>T allele as reported previously. 19 In brief, the fibroblasts were digested into single cells with 0.05% trypsin (Life Technologies), serially diluted to a density of ≈1 to 5 cells/ mL and plated into 48-well plates. A portion of cells from each well were sampled for immunostaining analysis to evaluate the purity of the cell population. The selection steps were repeated until a pure population of fibroblasts was obtained. The selected population of fibroblasts was then reprogrammed separately to iPSCs ( Figure 3B ). The pluripotency of the resultant iPSC line was validated with standard procedures (see Methods and Table II in the online-only Data Supplement for the materials and Figure I in the online-only Data Supplement). We confirmed that both the LAMP2-WT and LAMP2-c.520C>T iPSC clones from Pt-I-1 and LAMP2-c.520C>T iPSC clones from Pt-II-1 and Pt II-2 had an unchanged genotype compared with their parent cells ( Figure 3C ). The LAMP2-WT iPSC clone from Pt-I-1 and a wild-type iPSC clone from a healthy donor served as controls. These clones of iPSCs were maintained and differentiated into cardiomyocytes for subsequent functional assessment. As indicated in Figure 3D and E, the LAMP2 protein production abilities of these cell lines remained unchanged after cardiac differentiation.
In Vitro Functional Assessments
For autophagy dysfunction, accumulation of autophagic material was evaluated with antibody-based detections of LC3-I, LC3-II, and p62 in the presence of rapamycin (an activator of autophagy) or bafilomycin A (a blocker of lysosomal autophagosome clearance) as recommended by published guidelines. 20 When necessary, cells of interest were also treated with MG132, a proteasome inhibitor, to evaluate the role of the ubiquitin-proteasome pathway. The contractility of cardiomyocytes was assessed with a video-based edge detection system that continuously measured the movement of a selected point at the edge of isolated cardiomyocytes or iPSCs-CMs (IonOptix, Dublin, Ireland), and high-speed confocal laser scanning microscopy was used to assess the calcium handling properties of the iPSC-CMs (Methods in the online-only Data Supplement).
Statistical Analysis
Continuous variables are expressed as mean±SEM. Statistical comparisons between 2 groups were performed with the A, Immunofluorescent staining analysis was performed to evaluate the distribution of lysosome-associated membrane protein-2 (LAMP2) and light chain 3 (LC3) in the myocardium of Pt-I-1: 46.73±15.73% (n=1500 cells from 29 fields) of the analyzed cells were LAMP2-positive, whereas 25.74±11.42% (n=1500 cells from 29 fields) of the analyzed cells showed accumulation of LC3 punctae. The regions showing LC3 and cardiac troponin T (cTnT) colocalization are highlighted. Scale bar=100 μm. B, Periodic acid-Schiff staining was used to evaluate the glycogen levels in the myocardium of Pt-I-1. Amylase treatment was used to confirm that the positive results were not due to artifact. The myocardium of Pt-I-1 showed a mosaic pattern of glycogen deposition status; ≈37.85±3.65% (n=500 cells from 8 fields) of the cells were heavily stained, significantly more (P<0.01) than observed in healthy individuals (4.47±0.50%, n=500 cells from 8 fields). Scale bar=50 μm. **P<0.01. A, The protein level and cellular distribution of lysosome-associated membrane protein-2 (LAMP2) in fibroblasts derived from patients with the LAMP2-c.520C>T mutation were evaluated by Western blot and immunostaining analysis. A mosaic pattern of LAMP2 production could be observed in the fibroblasts derived from Pt-I-1. B, The LAMP2-deficient Pt-I-1 fibroblasts were separated from the LAMP2-producing counterparts with the single cell splitting, and the purity of the cell population was confirmed by immunostaining analysis. C, The fibroblasts were reprogrammed into iPSCs, and the genotypes were confirmed with genomic DNA sequencing analysis. D, The protein level and the cellular distribution of LAMP2 of the iPSCs and iPSC-CMs were evaluated with Western blot analysis. E, The cellular LAMP2 protein distribution of the iPSCs and the iPSC-CMs was evaluated by immunostaining analysis. Enlarged views of the area of interest showed that the LAMP2 proteins were located mainly in perinucleic regions of the iPSC-CMs. Scale bar=100 μm. cTnT indicates cardiac troponin T. 
RESULTS

Whole-Exome Sequencing Analysis and Functional Effect of LAMP2-c.520C>T Mutation
The case for Pt-I-1 passed the FASTQC sequenced read quality screening ( Figure IIA in the online-only Data Supplement). In brief, a total of 51 323 309 reads (60.14%) were mapped to targets and 150 bp flanking the targets. One splice acceptor site variation was located in the ACRC gene. The remaining 9 candidate single-nucleotide polymorphisms were located in the following genes (ordered by their physical positions on the X chromosome): ARSF, OTUD6A, GDPD2, MAGEE2, LAMP2, ODZ1, SMAR-CA1, GPR112, and MAGEC1. The functional significance of the polymorphisms of these genes was checked via online databases such as Genecards. Only LAMP2 appeared to be related to the pathogenesis of cardiomyopathy. Indeed, the nonsense mutation (c.520C>T) at exon 4 of the LAMP2 gene identified by exome sequencing has also been described previously in Danon disease. 17 Functionally, this G>A transition substitution (chromosome X:119,466,888; Figure This suggested that the clinical phenotypes were due to LAMP2 protein deficiency rather than toxicity of the truncated protein.
Histological Features
Immunofluorescent analysis demonstrated that 50% to 80% of LAMP2-deficient iPSC-CMs showed a distinct pattern of myofibril disorganization compared with ≈10% to 15% of the LAMP2-producing IPSC-CMs, as defined by punctate distribution of sarcomeric α-actinin over a quarter of the total cellular area (P<0.01). 21 The LAMP2deficient iPSC-CMs were also significantly larger than the LAMP2-producing iPSC-CMs (P<0.01; Figure 4A ). In addition, accumulation of LC3 punctate was observed in >70% of LAMP2-deficient iPSC-CMs but in <5% of the LAMP2-producing iPSC-CMs (P<0.01; Figure 4B , top).
Similarly, a significantly higher percentage of cells with excessive glycogen deposition were observed in the LAMP2-deficient iPSC-CMs (≈60%-70%) compared with the LAMP2-producing iPSC-CMs (<20%; P<0.01; Figure 4B, bottom).
To further confirm that LAMP2 deficiency, rather than clonal variation, is the direct cause of the observed phenotypic abnormalities in patient-specific iPSC-CMs, we silenced the endogenous LAMP2 expression in nondisease (line IMR90) iPSC-CMs using shRNAs technology. LAMP2-silenced iPSC-CMs, not those treated with negative control shRNA vector, showed myofibril disorganization similar to LAMP2-deficient iPSC-CMs ( Figure III 
LAMP2-Deficient iPSC-CMs Exhibited Impaired Autophagy
Immunostaining analysis demonstrated the accumulation of LC3-positive aggregates in LAMP2-deficient iPSC-CMs. To reveal the possible causes, we further evaluated the changes in the LC3-I and LC3-II level in the presence of autophagy activator (rapamycin) and inhibitor (bafilomycin A1).
As shown in Figure 5A and 5B (left), both rapamycin and bafilomycin increased the LC3-II protein level in the LAMP2-producing and LAMP2-deficient iPSC-CMs. This indicated that autophagy occurred in both of these lines. However, under all conditions, the LC3-II protein level in the LAMP2-deficient iPSC-CMs (Pt-I-1-LAMP2-c.520C>T) was significantly higher compared with that in LAMP2producing iPSC-CMs.
To evaluate the degree of autophagy failure in the LAMP2-deficient iPSC-CMs, we further compared the LC3-II/LC3-I ratios. At baseline (dimethyl sulfoxide control), the LC3-II/LC3-I ratio was ≈7.8-fold higher in the LAMP2-deficienct iPSC-CMs compared with the LAMP2producing iPSC-CMs ( Figure 5B ). Rapamycin treatment caused an ≈3-fold increase in the LC3-II/LC3-I ratio in the LAMP2-producing iPSC-CMs (P<0.01) compared with only an ≈1.8-fold increase in LAMP2-deficient iPSC-CMs (P<0.05). Similarly, bafilomycin treatment without rapamycin caused a 13-fold increase in the LC3-II/LC3-I ratio in LAMP2-producing iPSC-CMs (P<0.01) but only an approximate 1.8-fold increase in LAMP2-deficient iP-SC-CMs (P<0.01). A similar trend was also observed in iPSC-CMs treated with both rapamycin and bafilomycin. These results indicated that autophagy worked better in LAMP2-producing iPSC-CMs because both the LC3-II levels and LC3-II/I ratio were higher after treatment with either rapamycin or bafilomycin with or without rapamycin. On the contrary, the autophagy flux was reduced in the LAMP2-deficient iPSC-CMs because they had a blunted response to bafilomycin (with or without rapamycin) owing to the significantly higher baseline level of LC3-II and LC3-II/I ratio. On the basis of the functional properties of LAMP2, we speculated that the increased accumulation of autophagic material was due to failure to clear the autophagosomes rather than autoactivation of autophagy. To confirm this, we further evaluated the degradation of endogenous substrates by measuring the level of p62. As shown in Figure 5C , rapamycin treatment caused a significant reduction in the p62 level in the LAMP2-producing iPSC-CMs (P<0.05), suggesting that the activation of autophagy increased the clearance of p62. On the contrary, rapamycin treatment further increased the level of p62 in LAMP2-deficient iPSC-CMs. Similar results were observed in iPSC-CMs treated with bafilomycin (Figure 5C ). These findings indicate that LAMP2-deficient iP-SC-CMs cannot clear the autophagic cargoes efficiently.
These data suggest that the accumulation of autophagic material in the LAMP2-deficient iPSC-CMs was due to failure in autophagosome clearing rather than overactivation of the autophagy pathway.
LAMP2-Deficient iPSC-CMs Exhibit Impaired Calcium Handling Ability
Compared with LAMP2-producing iPSC-CMs, LAMP2deficient iPSC-CMs showed significantly decreased cellular contractility (P<0.01; Figure 6A ). Detailed analysis of the local and regional calcium handling properties of iPSC-CMs with ventricular phenotypes was performed (Methods, Results, and Figure IV in the online-only Data Supplement). 22 As shown in Figure 6B , LAMP2-deficient ventricular-like iPSC-CMs exhibited a significant reduction in amplitude (≈35% reduction), Vmax rise (≈35% reduction), and Vmax decay (≈40% reduction) values of intracellular calcium transients compared with LAMP2-producing ventricular-like iPSC-CMs (P<0.05). This reduction in calcium handling ability of the LAMP2-deficient cells is likely due to a reduced cellular protein level of calcium handling proteins. This assumption has been confirmed by Western blot analysis. As shown in Figure 6C , a significant reduction in the protein level of sodium-calcium exchanger (NCX1; 1.5-fold reduction; P<0.05), sarco/ endoplasmic reticulum Ca 2+ -ATPase 2 (2-fold reduction, P<0.05), and ryanodine receptor 2 (RYR2; 1.6-fold reduction; Pz<0.05) was observed in LAMP2-deficient iPSCs-CMs. It is interesting that there was no significant difference in mRNA level of the corresponding genes (ie, NCX1, ATP2A2 and RYR2) between the LAMP2-producing and LAMP2-deficient groups (Figure 6C, right) , suggesting that the reduced level of calcium handling protein was not the result of abnormalities at a transcription level.
To determine whether the contractile function can be restored by increasing the level of calcium handling proteins, we treated iPCS-CMs with MG132, which inhibited proteasome-associated protein degradation. As indicated in Figure V in the online-only Data Supplement, after 24 hours of MG132 treatment at 1 or 10 μmol/L, we observed significantly increased levels of ubiquitinated proteins in both LAMP-producing (P<0.01) and LAMP2deficient (P<0.05) iPSC-CMs. Nonetheless, lower doses of MG132 (1 μmol/L, 24 hours) did not cause any significant changes in the protein level of NCX1, sarco/ endoplasmic reticulum Ca 2+ -ATPase 2, or RYR2 or the contractility of iPSC-CMs, regardless of the LAMP2-protein productivity ( Figure VA and VB in the online-only Data Supplement). When the dose of MG132 was increased to 10 μmol/L, we observed a significant increase in the sarco/endoplasmic reticulum Ca 2+ -ATPase 2 (P<0.01) and RYR2 (P<0.02) protein level in LAMP2-deficient iPSC-CMs. Nevertheless, under this condition, the spontaneous contractions were abolished in >80% of LAMP2deficient iPCS-CMs (data not shown), and those beating cardiomyocytes also exhibited significantly reduced contractility (60% reduction; P<0.01). Similarly, the LAMP2producing iPSCs-CMs exhibited a significant reduction (by 48%; P<0.01) in contractility when exposed to 10 μmol/L of MG132. On the basis of these observations, inhibition of the proteasome degradation pathway cannot attenuate the impaired cardiac function associated with LAMP2 deficiency.
High-speed line-scan calcium imaging analysis revealed that LAMP2-deficient iPSC-CMs have an uneven propagation of calcium waves between the central and peripheral region ( Figure 6D ). Abnormal contractions in response to overwhelming sympathetic stimulation resulting from the inability to handle the increased calcium influx during excitation-contraction coupling are frequently observed in the failing human heart. We examined the effects of isoproterenol administration on the spontaneous calcium transient events of the iPSC-CMs. In all groups, the rate of spontaneous contractions as determined by the calcium transient wave was increased ( Figure 6E ). In the LAMP2-producing iPSC-CMs, the acceleration of spontaneous contractions persisted and eased only after washout of isoproterenol. Nonetheless, the acceleration was short-lived in LAMP2-deficient iPSC-CMs, and they arrested within 50 seconds of the application of isoproterenol ( Figure 6E) . This difference was like- A, The degree of cell shortening (contractility) during contraction of cardiomyocytes was recorded with the IonOptix Myocyte Contractility Systems (n=10 for each group). B, Intracellular calcium transients of iPSC-CMs were recorded with confocal laser microscopy. Representative tracings of the calcium transients recorded from iPSCs-derived ventricle-like myocytes, maximum calcium released (amplitude), maximum calcium release rate (Vmax rise ), and maximum calcium reuptake rates (Vmax decay ) are presented. n=18 for each group. C, Western blot (left) and semiquantitative polymerase chain reaction (right) analysis of the calcium handling proteins and corresponding transcripts. n=4 for each group. D, Regional calcium release was (Continued ) 
Effects of DNA Demethylation With 5AdC
After successfully modeling the phenotypes of Danon disease, we further explored the potential application of this iPSC-CM platform for drug screening. We hypothesized that pharmacological reactivation of the silenced wild-type Xi chromosome in Pt-I-1 would ameliorate the autophagy failure in Danon disease. We systematically screened different pharmacological agents that have been reported to reactivate the silenced Xi chromosome using the iPSC platform. 23, 24 Only the demethylating agent 5AdC could restore the production of LAMP2 proteins in the Pt-I-1-LAMP2-c.520C>T iPSCs ( Figure 7A ) via reactivation of the wild-type LAMP2 allele ( Figure 7B and Figure VIII in the online-only Data Supplement). It is interesting that when we extended the exposure time to 72 hours, a notable increase in LAMP2 protein production was observed in the 5AdCtreated group but not the PT-II-1 groups ( Figure IX in the online-only Data Supplement). Immunostaining analysis revealed the presence of LAMP2-positive cells in the Pt-I-1-LAMP2-c.520C>T iPSCs after 5AdC treatment ( Figure 7C ). Using Western blot analysis, we observed that LAMP2 protein production in the Pt-I-1 LAMP2-c.520C>T iPSCs after 5AdC treatment was ≈30% of that in the isogenic Pt-I-1-LAMP2-WT control. On the contrary, treatment of the Pt-I-1-LAMP2-WT iPSCs with 5AdC did not significantly alter the LAMP2 protein level ( Figure 7D ).
To confirm that 5AdC caused demethylation of the LAMP2 gene in the Pt-I-1 LAMP2-c.520C>T iPSCs, we collected genomic DNA from the treated and control cells and performed Infinium methylation analysis. Within the LAMP2 gene, 8 sites showed reduced methylation as reflected by a negative differential score compared with the nontreated samples ( Figure 7E ; for a complete list of X-linked sites showing altered methylation status after 5AdC treatment, please refer to the online-only Data Supplement). These findings indicate demethylation of the LAMP2 genes after 5AdC treatment. Next, we investigated whether similar effects of 5AdC in iPSCs could be observed in iPSC-CMs. Compared with iPSCs, only a small amount of LAMP2 protein could be detected by Western blot analysis in the Pt-I-1 LAMP2-c.520C>T cardiomyocytes after prolonged (7 days) 5AdC treatment ( Figure 8A) , suggesting that somatic cells are less sensitive to 5AdC than pluripotent iPSCs. This observation was further verified by immunostaining of the Pt-I-1 LAMP2-c.520C>T iPSC-CMs after 5AdC treatment. Only ≈10% of cardiomyo-cytes were positive for LAMP2 protein, and none were positive after dimethyl sulfoxide medium treatment ( Figure 8B ). It is interesting that decreased accumulation of LC3-positive punctae was observed not only in those LAMP2-producing iPSC-CMs but also in several LAMP2-negative iPSC-CMs on 5AdC treatment. To confirm this observation, we performed additional Western blot analysis, and the result indicated that 5AdC treatment significantly reduced both the LC3-I and LC3-II levels (P<0.05) regardless of the presence of rapamycin and bafilomycin ( Figure X in the online-only Data Supplement). Functionally, the Pt-I-1 LAMP2-c.520C>T iPSC-CMs showed significantly improved contractility and decreased susceptibility to isoproterenol-induced contractile arrest ( Figure 8C and 8D) after treatment with 5AdC, although only a relatively small proportion of iPSC-CMs resumed production of LAMP2 protein and autophagy. These observations suggest that complete abolition of LAMP2 protein production is required for the manifestation of severe cardiac dysfunction or that the improvement of contractile function can be due to the activation of other X-linked genes that help reduce the autophagy failure or enhance cardiac function.
Accordingly, we carried out differential knock-down experiments by transfecting the LAMP2-producing (line IMR90) iPSC-CMs with increasing amounts of LAMP2specific shRNA plasmids. As shown in Figure 8E , transfection of 2 μg shRNA plasmid reduced the LAMP2 protein level by >80% and confirmed that even such a substantial reduction in LAMP2 protein production did not significantly reduce the contractility of the transfected cells. This suggests that only a small amount of LAMP2 protein is required to maintain cardiac function.
Next, we further analyzed the X-linked genes that showed reduced methylation after 5AdC treatment. As indicated in the Table, although we could not identify any X-linked genes that directly affect the contractility of cardiomyocytes, various genes are involved in autophagy (eg, ATG4A) and the maintenance of cardiac function (eg, DMD), and numerous genes that are related to ubiquitin-proteasome pathways may have contributed to the improvement in function of cardiomyocytes and merit further investigation.
In addition to DNA demethylation, we evaluated the possibility of using translational read-through strategy as a means to restore LAMP2 protein production in male patients. Prior studies suggest that gentamycin treatment can overcome the premature termination of codon. [25] [26] [27] Unfortunately, we failed to observe any LAMP2 protein A, Pt-I-1-LAMP2-c.520C>T iPSCs were treated with various drugs for 24 hours, and the LAMP2 protein level was evaluated by Western blot analysis. B, When the treatment duration was prolonged to 72 hours, the LAMP2 protein level induced by 5AdC was ≈30% that of normal control (n=5; P<0.01). C, The percentage of cells showing LAMP2 protein production after 5AdC treatment (72 hours) in the Pt-I-1-LAMP2-c.520C>T group was evaluated by immunostaining. Compared with the dimethyl sulfoxide (DMSO)treated control group, 70.07±3.50% of the 5AdC-treated cells showed LAMP2 protein production (n=1000 cells (Continued ) production in fibroblasts derived from Pt-II-1 after treatment with gentamycin ( Figure XI in the online-only Data Supplement), suggesting that the translational readthrough action of gentamycin is a codon-specific effect that was not applicable to the LAMP2 mutation in this study. 25 
DISCUSSION
Danon disease is a fatal disease with diverse clinical presentations in male and female subjects. Clinical diagnosis is challenging. [7] [8] [9] In this family, we opted to apply whole-exome sequencing to diagnose the familial cardiomyopathy because of the distinct clinical presentations and phenotypes of the mother and her 2 sons. The search for a causal variation in this family led to the identification of a nonsense LAMP2 mutation (Q174X) in the X chromosome, known to cause Danon disease. 28 Next, we adopted the iPSC-CM platform to reproduce the histological and functional characteristics of Danon disease and gained novel mechanistic insights into the contribution of random inactivation of the wild-type and mutant LAMP2 on the X chromosome to the unusual phenotype of female patients with Danon disease. This study provides the first proof-ofprinciple demonstration that the silenced wild-type Xi chromosome in female subjects can be reactivated by use of the DNA demethylating agent 5AdC and serves as a potential novel therapeutic approach to ameliorate the disease phenotypes in fatal X-linked-related Danon disease.
In the study, we successfully generated iPSC lines from Pt-I-1, Pt-II-1, and Pt-II-2 who carried a nonsense mutation in the LAMP2 gene and an isogenic iPSC line with wild-type LAMP2 gene from Pt-I-1. The preselection of somatic cells with distinct X-chromosome inactivation status offers us a unique way to generate isogenic iPSCs that carry either the wild-type or the mutant LAMP2 allele for disease modeling and drug screening. Compared with iPSC-CMs from healthy controls and the wild type isogenic cell line, iPSC-CMs with active LAMP2c.520C>T allele failed to produce LAMP2 protein and exhibited autophagy failure with LC3-II accumulation and excessive glycogen deposition, myofibril disorganization, and cellular hypertrophy. Next, we demonstrated that LAMP2-deficient iPSC-CMs have impaired calcium handling and contractile properties compared with isogenic wild-type and control iPSC-CMs. Indeed, similar structural and functional abnormalities were observed in primary live cardiomyocytes isolated from the cardiac explanted samples of Pt-I-1, suggesting that patientspecific iPSC-CMs can reproduce the clinical phenotypes in human cardiomyopathy. More important, our in vitro data provide evidence that the mosaic pattern of somatic cells in Danon disease resulting from random X-chromosome inactivation can create 2 distinct populations of iPSC-CMs with or without LAMP2 production that mimic the clinical phenotypes, as observed from histological examination in our female patients. The presence of LAMP2-producing cardiomyocytes in female patients, as in Pt-I-1, might account for the late onset and less severe clinical phenotypes seen in female compared with male patients.
We further speculated that restoration of expression of wild-type LAMP2 alleles can potentially ameliorate the disease phenotypes in female patients with Danon disease. Among various drugs tested, 5AdC induced demethylation of the LAMP2 genes and restored LAMP2 production in both the iPSCs and iPSC-CMs derived from Pt-I-1-LAMP2-c.520C>T fibroblasts. Compared with iPSCs, iPSC-CMs were less susceptible to the effects of 5AdC, in which only ≈10% of treated cells showed detectable LAMP2 protein production. Unexpectedly, the accumulation of LC3 punctae and the contractile function of the 5AdC-treated iPSC-CMs were significantly improved despite a relatively low percentage of treated cells showing reactivation of the wildtype LAMP2 allele. To further validate this observation, we reduced the LAMP2 protein level in the LAMP2producing iPSC-CMs with different concentrations of LAMP2-specific shRNA plasmids. Even at >85% reduction in LAMP2 protein levels, the iPSC-CMs showed no significant reduction in contractile function. These observations are in accordance with the previous observation that female patients with Danon disease and only ≈25% LAMP2-positive myocardium still have a much later disease onset than their male counterparts with the same LAMP2 mutation. 13 These findings suggest that even a small population of normal cardiomyocytes can help maintain cardiac function in the diseased myocardium and thus ameliorate the disease phenotype caused by the affected cells. Our data provide evidence that 5AdC is a potential novel therapeutic approach for female patients with Danon disease and warrants further clinical evaluation for future therapeutic use. Although the demethylating effect of 5AdC is global (see Figure 7 Continued. from 10 fields). D, The presence of the wild-type LAMP2 transcript in the 5AdC-treated cells was confirmed by reverse transcription-polymerase chain reaction analysis followed by direct sequencing analysis. E, The demethylating effects of 5AdC on the Pt-I-1-LAMP2-c.520C>T iPSCs were evaluated with Infinium methylation analysis. Genomic DNA isolated from the control and 5AdC-treated cells was extracted and resolved on 0.8% agarose gel for quality assurance and subjected to methylation array analysis. Eight sites within the LAMP2 gene showing reduced methylation compared with the control group (negative differential scores) were identified, and the corresponding sequences are listed. the online-only Data Supplement for the list of X-linked genes responsive to 5AdC treatment) and the potential off-target effects of 5AdC may present some clinical concerns, it has been clinically used to treat various hematologic malignancies with an acceptable side-effect profile. [29] [30] [31] Some of these off-target effects might have been desirable. In this study, we have identified 12 genes related to the ubiquitin-proteasome system that were demethylated after 5AdC treatment (Table) . In the absence of a functional autophagy clearance system, the ubiquitin-proteasome pathway should be an important pathway for cardiomyocytes to clear obsolete substances. 32, 33 Our observation that blocking of the proteasome pathway with MG132 further reduced the contractility of LAMP2-deficient iPSC-CMs also provides indirect evidence to support this hypothesis. Activation or enhancement of the ubiquitin-proteasome pathways can be another potential strategy to attenuate the cardi-ac dysfunction caused by LAMP2 deficiency and merits further investigation.
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SOURCES OF FUNDING
UBA1
Ubiquitin-like modifier activating enzyme 1 NM_153280 28
UBE2A
Ubiquitin-conjugating enzyme E2A NM_181762 13
UBL4A
Ubiquitin-like protein 4A NM_014235 12
UBQLN2
Ubiquilin-2 NM_013444 7
USP11
Ubiquitin carboxyl-terminal hydrolase 11 NM_004651 7
USP27X
Deubiquitinating enzyme USP27X NM_001145073 5
USP51
Ubiquitin carboxyl-terminal hydrolase 51 NM_201286 11
USP9X
Probable ubiquitin carboxyl-terminal hydrolase FAF-X NM_001039590 11 5AdC indicates 5-aza-2'-deoxycytidine.
